Kennoki Norifumi, Saguchi Toru, Sano Toru, Takara Yuki, Moriya Tomohisa, Shirota Natsuhiko, Otaka Jun, Chiba Naokazu, Kawachi Shigeyuki, Serizawa Hiromi, Koizumi Kiyoshi, Tokuuye Koichi
Department of Radiology, Tokyo Medical University Hospital, Tokyo, Japan.
Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
BJR Case Rep. 2019 Jan 25;5(1):20180066. doi: 10.1259/bjrcr.20180066. eCollection 2019 Feb.
Very few studies have been published on the long-term histopathologic follow-up of spherical embolic agents after their injection. To our knowledge, there are no reports in the literature regarding pathological analysis of the transvascular migration of HepaSphere particles. We here report a case of a patient with hepatocellular carcinoma (HCC) who underwent liver transplantation 12 months after drug eluting microsphere transcatheter arterial chemoembolization (DEM-TACE), and long-term histopathologic follow-up of the microspheres was performed. Furthermore, to our knowledge, this is the first report in which transvascular migration of a HepaSphere particle was confirmed histologically. A 60-year-old male with chronic hepatitis B was treated with entecavir and seroconversion was obtained. The patient had decompensated cirrhosis, and desired to undergo living donor liver transplantation (LDLT). However, 2 HCC tumors of 3 cm or less were detected in his liver. The transplantation surgeon proposed DEM-TACE as a bridge therapy. The HCCs were located in the right lobe and lateral segment of the liver. A 1.9 F preshaped microcatheter (ProgreatΣ, Terumo, Japan) was selectively inserted into the A3 and anterior segmental branch, 10 mg of epirubicin was injected into each artery, and the arteries were embolized with 7 mg and 13 mg of HepaSphere loaded with epirubicin, respectively. Two months later, contrast-enhanced CT displayed a complete response. At that time, lung metastasis was suspected, but after partial lung resection, the patient was diagnosed as having inflammatory granuloma. One year after DEM-TACE treatment, LDLT was performed. No cancerous cells were detected in the area where the tumor was present, but 22 HepaSphere particles were detected. All particles were present in the interstitium. Furthermore, the transvascular migration of a HepaSphere particle was histologically confirmed. The largest and smallest HepaSphere diameters were 241.6 ± 52.5 µm and 186.5 ± 41.4 µm, respectively, and deformity was 22.6% ± 13.0 %. All the HepaSpheres detected in the examined pathological specimen were noted to be extravascular.
关于球形栓塞剂注射后的长期组织病理学随访研究发表得很少。据我们所知,文献中尚无关于HepaSphere颗粒经血管迁移的病理分析报告。我们在此报告一例肝细胞癌(HCC)患者,其在药物洗脱微球经导管动脉化疗栓塞术(DEM-TACE)后12个月接受了肝移植,并对微球进行了长期组织病理学随访。此外,据我们所知,这是第一份通过组织学证实HepaSphere颗粒经血管迁移的报告。一名60岁慢性乙型肝炎男性患者接受恩替卡韦治疗并实现血清学转换。该患者患有失代偿期肝硬化,希望接受活体肝移植(LDLT)。然而,在其肝脏中检测到2个直径3厘米或更小的HCC肿瘤。移植外科医生建议采用DEM-TACE作为桥接治疗。HCC位于肝脏右叶和外侧段。将一根1.9F预塑形微导管(ProgreatΣ,泰尔茂,日本)选择性插入A3和前段分支,分别向每条动脉注入10mg表柔比星,并用分别装载7mg和13mg表柔比星的HepaSphere栓塞动脉。两个月后,增强CT显示完全缓解。当时怀疑有肺转移,但部分肺切除术后,患者被诊断为炎性肉芽肿。DEM-TACE治疗一年后,进行了LDLT。在肿瘤所在区域未检测到癌细胞,但检测到22个HepaSphere颗粒。所有颗粒均存在于间质中。此外,通过组织学证实了一个HepaSphere颗粒的经血管迁移。HepaSphere的最大和最小直径分别为241.6±52.5μm和186.5±41.4μm,变形率为22.6%±13.0%。在所检查的病理标本中检测到的所有HepaSphere均位于血管外。